recurrent ovarian clear cell adenocarcinoma
Showing 1 - 7 of 7
Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid
Not yet recruiting
- Recurrent Endometrial Carcinoma
- +8 more
- BET Bromodomain Inhibitor ZEN-3694
- +7 more
- (no location specified)
Jul 15, 2023
Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma, Recurrent Fallopian Tube Carcinoma Trial in Rochester (Biopsy,
Not yet recruiting
- Fallopian Tube Carcinosarcoma
- +14 more
- Biopsy
- +6 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jun 28, 2023
Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma
Active, not recruiting
- Recurrent Endometrial Endometrioid Adenocarcinoma
- +4 more
-
Anchorage, Alaska
- +584 more
Jan 28, 2023
Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in
Not yet recruiting
- Ovarian Clear Cell Adenocarcinoma
- +14 more
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140
- +4 more
-
Buffalo, New York
- +1 more
Dec 16, 2022
Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma Trial in
Recruiting
- Fallopian Tube Carcinosarcoma
- +28 more
- Pegylated Liposomal Doxorubicin Hydrochloride
- Peposertib
-
Aurora, Colorado
- +7 more
Sep 2, 2022
Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma Trial in
Recruiting
- Fallopian Tube Mucinous Adenocarcinoma
- +49 more
- Cediranib Maleate
- +5 more
-
Anchorage, Alaska
- +373 more
Aug 17, 2022
Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Platinum-Resistant
Recruiting
- Recurrent Fallopian Tube Clear Cell Adenocarcinoma
- +5 more
- Etigilimab
- Nivolumab
-
Houston, TexasM D Anderson Cancer Center
Nov 22, 2021